0000899243-22-038520.txt : 20221214 0000899243-22-038520.hdr.sgml : 20221214 20221214205650 ACCESSION NUMBER: 0000899243-22-038520 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221212 FILED AS OF DATE: 20221214 DATE AS OF CHANGE: 20221214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Meisner Lara CENTRAL INDEX KEY: 0001883986 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 221463488 MAIL ADDRESS: STREET 1: C/O VIRIDIAN THERAPEUTICS, INC. STREET 2: 203 CRESCENT STREET, BLDG. 17, SUITE 102 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-12-12 0 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001883986 Meisner Lara C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 0 1 0 0 General Counsel and Secretary Common Stock 2022-12-12 4 M 0 600 23.03 A 600 D Common Stock 2022-12-12 4 S 0 600 28.05 D 0 D Common Stock 2022-12-14 4 M 0 15656 23.03 A 15656 D Common Stock 2022-12-14 4 S 0 15656 28.12 D 0 D Stock Option (Right to Buy) 23.03 2022-12-12 4 M 0 600 0.00 D 2031-09-22 Common Stock 600 78900 D Stock Option (Right to Buy) 23.03 2022-12-14 4 M 0 15656 0.00 D 2031-09-22 Common Stock 15656 63244 D This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.02 to $28.115. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $28.00 to $28.33. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The option vested 25% on December 2, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. /s/ Kristian Humer, Attorney-in-Fact for Lara Meisner 2022-12-14